Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2022 Filed Jul 21, 2022 20:48 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 4,561 | $287.83 | $1,312,792.63 |
DisclosureSEC source: 0000899243-22-026486 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,418 F2 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.11 to $288.10). Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:48 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 963 | $286.72 | $276,111.36 |
DisclosureSEC source: 0000899243-22-026486 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,979 F2 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $286.72 (range $286.07 to $287.01). Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:48 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 7,338 | $155.57 | $1,141,572.66 |
DisclosureSEC source: 0000899243-22-026486 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:48 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 10,427 | $187.53 | $1,955,375.31 |
DisclosureSEC source: 0000899243-22-026486 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 100 shares previously purchased under the issuer's Employee Stock Purchase Plan. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:32 UTC |
Upadhyay SuketuDirector
|
GrantDeferred Stock Units · Derivative | 41.794 | $289.23 | $12,088.08 |
DisclosureSEC source: 0000899243-22-026340 · doc4.xml · derivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41.794 Underlying: Common Stock · 41.794 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:33 UTC |
MCKENZIE DIANADirector
|
GrantDeferred Stock Units · Derivative | 95.081 | $289.23 | $27,500.28 |
DisclosureSEC source: 0000899243-22-026342 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,825.766 Underlying: Common Stock · 95.081 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:35 UTC |
SACHS BRUCE IDirector
|
GrantDeferred Stock Units · Derivative | 151.264 | $289.23 | $43,750.09 |
DisclosureSEC source: 0000899243-22-026349 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,974.772 Underlying: Common Stock · 151.264 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 20:05 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 11,689 | $291.30 | $3,405,005.70 |
DisclosureSEC source: 0000899243-22-024385 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,153 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $291.30 (range $291.00 to $291.49). Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:06 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 311 | $271.24 | $84,355.64 |
DisclosureSEC source: 0000899243-22-020677 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,512 Read SEC document |
| May 18, 2022 Filed May 19, 2022 20:05 UTC |
Upadhyay SuketuDirector
|
GrantCommon Stock | 1,558 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018783 · doc4.xml · nonDerivative · entry 1 Upadhyay Suketu · CIK 0001533149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558 F1 · shares: Restricted stock unit grant vests on 5/18/2023. Read SEC document |
| May 17, 2022 Filed Feb 3, 2023 21:56 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
GiftCommon Stock | 1,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006973 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held in Trust Disclosed balance after: 11,052 Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 35 | $254.36 | $8,902.60 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 5 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,334 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $254.36 (range $254.15 to $254.57). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 34 | $253.87 | $8,631.58 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 4 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,369 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $253.87 (range $253.14 to $254.13). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 20 | $252.49 | $5,049.80 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 3 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,403 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $252.49 (range $252.12 to $253.11). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 19 | $251.57 | $4,779.83 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,423 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $251.57 (range $251.05 to $251.81). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:18 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 25 | $250.77 | $6,269.25 |
DisclosureSEC source: 0000899243-22-018604 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,442 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $250.77 (range $250.00 to $250.90). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:22 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 8 | $254.44 | $2,035.52 |
DisclosureSEC source: 0000899243-22-018605 · doc4.xml · nonDerivative · entry 5 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,749 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $254.44 (range $254.35 to $254.57). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:22 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 15 | $253.99 | $3,809.85 |
DisclosureSEC source: 0000899243-22-018605 · doc4.xml · nonDerivative · entry 4 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,757 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $253.99 (range $253.33 to $254.32). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:22 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 7 | $252.43 | $1,767.01 |
DisclosureSEC source: 0000899243-22-018605 · doc4.xml · nonDerivative · entry 3 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,772 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $252.43 (range $252.15 to $253.07). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:22 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 8 | $251.37 | $2,010.96 |
DisclosureSEC source: 0000899243-22-018605 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,779 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $251.37 (range $251.00 to $251.88). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:22 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 7 | $250.56 | $1,753.92 |
DisclosureSEC source: 0000899243-22-018605 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,787 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $250.56 (range $250.00 to $250.87). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:21 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 40 | $254.19 | $10,167.60 |
DisclosureSEC source: 0000899243-22-018610 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,760 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $254.19 (range $253.74 to $254.57). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:21 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 10 | $252.66 | $2,526.60 |
DisclosureSEC source: 0000899243-22-018610 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,800 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:21 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 10 | $251.43 | $2,514.30 |
DisclosureSEC source: 0000899243-22-018610 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,810 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:21 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 32 | $250.78 | $8,024.96 |
DisclosureSEC source: 0000899243-22-018610 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,820 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $250.78 (range $250.35 to $250.97). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:21 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 20 | $249.35 | $4,987.00 |
DisclosureSEC source: 0000899243-22-018610 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,852 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $249.35 (range $249.24 to $249.45). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:21 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 10 | $247.95 | $2,479.50 |
DisclosureSEC source: 0000899243-22-018610 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,872 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:21 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 11 | $246.21 | $2,708.31 |
DisclosureSEC source: 0000899243-22-018610 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,882 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $246.21 (range $245.78 to $246.25). Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 36 | $275.09 | $9,903.24 |
DisclosureSEC source: 0000899243-22-017086 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,660 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $275.09 (range $275.00 to $275.11). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 3 | $264.37 | $793.11 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 7 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,730 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 32 | $262.06 | $8,385.92 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 6 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,733 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $262.06 (range $261.89 to $262.23). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 48 | $261.15 | $12,535.20 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 5 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,765 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $261.15 (range $260.79 to $261.63). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 80 | $259.45 | $20,756.00 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,813 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $259.45 (range $258.98 to $259.90). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 60 | $258.21 | $15,492.60 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,893 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $258.21 (range $257.98 to $258.61). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 100 | $257.18 | $25,718.00 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,953 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $257.18 (range $256.68 to $257.47). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 20 | $254.87 | $5,097.40 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,053 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 6 | $264.37 | $1,586.22 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 7 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,903 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 91 | $261.91 | $23,833.81 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 6 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,909 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $261.91 (range $261.69 to $262.09). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 80 | $260.82 | $20,865.60 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 5 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $260.82 (range $260.49 to $261.15). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 120 | $259.75 | $31,170.00 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 4 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,080 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $259.75 (range $259.35 to $260.14). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 120 | $258.90 | $31,068.00 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $258.90 (range $258.32 to $259.19). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 280 | $257.51 | $72,102.80 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,320 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $257.51 (range $257.15 to $258.09). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:09 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 40 | $255.40 | $10,216.00 |
DisclosureSEC source: 0000899243-22-016638 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 4 | $264.37 | $1,057.48 |
DisclosureSEC source: 0000899243-22-016641 · doc4.xml · nonDerivative · entry 7 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,696 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 65 | $261.79 | $17,016.35 |
DisclosureSEC source: 0000899243-22-016641 · doc4.xml · nonDerivative · entry 6 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,700 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $261.79 (range $261.39 to $262.23). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 23 | $260.44 | $5,990.12 |
DisclosureSEC source: 0000899243-22-016641 · doc4.xml · nonDerivative · entry 5 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,765 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $260.44 (range $260.35 to $261.31). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 75 | $259.58 | $19,468.50 |
DisclosureSEC source: 0000899243-22-016641 · doc4.xml · nonDerivative · entry 4 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,788 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $259.58 (range $259.24 to $260.07). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 43 | $258.46 | $11,113.78 |
DisclosureSEC source: 0000899243-22-016641 · doc4.xml · nonDerivative · entry 3 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,863 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $258.46 (range $258.11 to $258.93). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 90 | $257.49 | $23,174.10 |
DisclosureSEC source: 0000899243-22-016641 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,906 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $257.49 (range $257.05 to $257.87). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 20 | $255.47 | $5,109.40 |
DisclosureSEC source: 0000899243-22-016641 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,996 F1 · kind: Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $255.47 (range $255.23 to $255.70). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.